China's affiliated company, CNR Haiduwei BNCT Boron Drug, has been approved for clinical use.

The Zhitong Finance and Economics APP reports that China Tongfu (01763) has announced that the subsidiary company Shenzhen China Nuclear Haiduwei Biological Technology Co., Ltd. (China Nuclear Haiduwei) has recently received approval for clinical trial application of self-developed Class 2.2 innovative drug "Boron [10B] flun" (BNCT Boron Medicine: Boron Neutron Capture Therapy) from the Center for Drug Evaluation of the National Medical Products Administration (CDE) official website (notification number: 2025LP03425).